Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that ...

Mexiletine appears to be safe and is likely an effective treatment for managing symptoms of myotonia (delayed muscle relaxation after a contraction) in people wit ...

even with conservative treatment of prolonged PR intervals and bundle branch block. Relatively few patients with myotonic dystrophy appear to require implanted cardiac pacemakers.

In this article, I noted about the opportunity for the company to develop its candidate DYNE-101 for the treatment of patients with Myotonic Dystrophy Type I [DM1]. It was able to have its drug ...

Myotonic dystrophy type 1 (DM1), a genetic disorder ... Future research will need to explore treatment options to improve metabolism in the kidney as a therapy for patients with DM1.

drug program for the treatment of myotonic dystrophy type 1 (DM1), a form of muscular dystrophy. The data will be presented in an oral session at the Muscular Dystrophy Association (MDA ...

Myotonic dystrophy type 1 (DM1), a genetic disorder ... Future research will need to explore treatment options to improve metabolism in the kidney as a therapy for patients with DM1.

Building on initial awards totalling over £1.6m, a team of researchers are receiving further investment to explore the capabilities of quantum ...

Avidity Biosciences, Inc.’s RNA share price has surged by 11.33%, which has investors questioning if this is right time to sell.

PepGen Inc. said it will pause a mid-stage study of its Duchenne muscular dystrophy treatment due to a safety ... as well as its studies in myotonic dystrophy type 1. CONNECT2, was open in the ...

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 24th Annual ...